The global antisense oligonucleotides market size was estimated to be US$ 1.7 billion in 2021 and is expected grow at a CAGR of 9.5% between 2023 to 2032.
15-25 nucleotide long oligonucleotides that are designed to tie complementary RNA targets for degradation are known as Antisense oligonucleotides (ASO). By altering the synthesis of a specific protein ASOs can be used to block disease processes. They offer promising treatment options for various medical disorders. ASOs can target specific malfunctioning gene, interfere with RNA function at a cellular level and can also be silenced or modulated. A wide range of autoimmune disorders which are untreatable with available drugs can be treated by ASOs as they allow modifications in the immune system.
ASOs have minimal side effects and can be controlled easily compared to other drugs. Furthermore, when compared to other biologic therapies it is easier to scale up the commercial scale GMP production of Antisense Oligonucleotides.
Rise in the incidences of autoimmune and chronic diseases
The rising number of patients suffering from autoimmune diseases such as multiple myeloma, Waldenstrom macroglobulinemia, hypogammaglobinemia and chronic inflammatory demyelinating polyneuropathy (CIDP) will drive market growth.
Increasing research and development activities
The number of research and development activities for autoimmune/chronic disorders has increased and there is an increase in investment for developing new and advanced technologies that will bolster this market growth during the forecast period.
Antisense Oligonucleotides Market Share Analysis, by Geography (2021)
COVID-19 impact on Antisense Oligonucleotides market
The global pandemic of COVID-19 has offered pharmaceutical companies’ numerous opportunities to increase their research and development budgets in order to offer treatment support to critically ill patients. Also, the increase of activities by the regulatory authorities to approve new treatments has further bolstered this market growth.
Antisense Oligonucleotides market challenges
Lack of skilled professionals
There is a shortage of skilled healthcare professionals and also lack of training to administer Antisense Oligonucleotide therapies. The lack of awareness and skills could be restraining factors for market growth.
Strict government regulations
Government regulators around the world have imposed various stringent regulations and standards pertaining to new antisense oligonucleotides products which are expected to restrain market growth.
Key players in global antisense oligonucleotides market include Ionis Pharmaceuticals Inc., Sarepta Therapeutics Inc., Biogen Inc., Alnylam Pharmaceuticals Inc., Antisense Therapeutics Ltd., Isarna Therapeutics GmbH Arrowhead Pharmaceuticals Inc., Atlantic pharmaceuticals Inc., Enzon Pharmaceuticals Inc., Bio-Path Holdings Inc., Glaxo smith Kline Plc., Gene Signal International SA., Geron Corporation, Gradlis Inc., ICO Therapeutics Inc., Aptose Biosciences Inc., Marina Biotech Inc., miRagen Therapeutics Inc., Synlogic Inc., OncoGenex Pharmaceuticals Inc., Pharmaxis Ltd., Rexahn Pharmaceuticals Inc., Regulus Therapeutics Inc., Rxi Pharmaceuticals Inc and others.
Market Segmentation:
By Drugs
By Therapeutic Application
By Distribution Channel
By Geography
The global antisense oligonucleotides market is estimated to expand at a CAGR of 9.5% through 2032.
The rising number of patients suffering from autoimmune diseases such as multiple myeloma, Waldenstrom macroglobulinemia, hypogammaglobinemia and chronic inflammatory demyelinating polyneuropathy (CIDP) will drive market growth
Based on drugs, the antisense oligonucleotides market is segmented into Pegaptanib, Eteplirsen, Mipomersen and Others.
Enzon Pharmaceuticals Inc., Bio-Path Holdings Inc., Glaxo smith Kline Plc., Gene Signal International SA and Geron Corporation are the top 5 antisense oligonucleotides manufacturers.
The major applications of antisense oligonucleotides include Cancer, Diabetes, Ocular diseases, Amyotrophic Lateral Sclerosis (ALS), Spinal Muscular Atrophy Hemorrhagic fever viruses, HIV/AIDS, Cytomegalovirus retinitis and Others.
Copyright © 2024 Same Page Management Consulting Pvt. Ltd. (insightSLICE) | All Rights Reserved